➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: August 9, 2020

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Nitropress, and when can generic versions of Nitropress launch?

Nitropress is a drug marketed by Abbott, Abbvie, and Hospira. and is included in four NDAs.

The generic ingredient in NITROPRESS is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.

US ANDA Litigation and Generic Entry Outlook for Nitropress

A generic version of NITROPRESS was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.

  Start Trial

Drug patent expirations by year for NITROPRESS
Drug Prices for NITROPRESS

See drug prices for NITROPRESS

Recent Clinical Trials for NITROPRESS

Identify potential brand extensions & 505(b)(2) entrants

American Heart AssociationPhase 2
Emory UniversityPhase 2

See all NITROPRESS clinical trials

Pharmacology for NITROPRESS
Drug ClassVasodilator
Physiological EffectVasodilation

US Patents and Regulatory Information for NITROPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 071555-001 Nov 16, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 070566-001 Jun 9, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Abbvie NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 018450-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.